Description: Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Home Page: www.strides.com
Strides House
Bengaluru,
560076
India
Phone:
91 80 6784 0000
Officers
| Name | Title |
|---|---|
| Mr. Arun Kumar Pillai B.Com. | Founder & Executive Chairperson |
| Mr. Badree Komandur | MD & Group CEO |
| Ms. Manjula Ramamurthy | Compliance Officer & Company Secretary |
| Mr. Aditya Arun Kumar | Executive Director of Business Development & Director |
| Mr. Vikesh Kumar | Group CFO & Chief Investor Relations Officer |
| Mr. P. V. S. Ramaraju | Chief Operating Officer |
| Sormistha Ghosh | Group General Counsel, Chief Risk Officer & Chief Sustainability Officer |
| Ms. Surabhi Loshali | Group Chief Human Resource Officer |
| Mr. C. K. Sundar | Executive Vice President of Operations |
| Mr. Kevin P. Cook | Senior Vice President of Strides Pharma Inc. |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 35.2193 |
| Price-to-Book MRQ: | 2.7694 |
| Price-to-Sales TTM: | 1.4263 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 3065 |